Obesity
Conditions
Interventions
The study will be a randomized, double-blind, placebo-controlled trial involving 150 individuals who meet the inclusion criteria. These participants will be randomly assigned to two groups: the interv
while the control group, also consisting of 75 participants, will receive a daily placebo capsule. The intervention will last for 12 weeks, and neither the researchers nor the participants will know t
G07.203.300.456
Sponsors
Universidade Estadual de Montes Claros
Universidade Estadual de Montes Claros
Eligibility
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Men and women; aged 18 to 35 years; Body Mass Index (BMI) greater than 30 kg/m² and body fat percentage above 25%, with stable body weight over the past six months; physically inactive; to be apparently healthy according to the Physical Activity Readiness Questionnaire
Exclusion criteria
Exclusion criteria: Musculoskeletal injury that limits the ability to perform moderate and vigorous intensity exercise during the study period; use of anti-inflammatory drugs and/or analgesics during the study period; use of any therapy for muscle pain during the study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| An improvement in the participants' metabolic parameters is expected following the use of the supplement, as evidenced by the evaluation of biochemical markers through laboratory tests conducted before and after the intervention. This includes a reduction in triglyceride levels, fasting glucose, and abdominal circumference, along with an increase in high-density lipoprotein (HDL) levels. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in Body Mass Index (BMI) to values below 30 kg/m² following the use of the supplement, measured through body composition analysis conducted before and after the intervention. | — |
Countries
Brazil
Contacts
Public ContactSérgio Sousa
Universidade Estadual de Montes Claros
Outcome results
None listed